Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2023-04-18 Share Issue/Capital Cha…
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - OCC 6 pages 28.0KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX by Orthocell Limited. It details the issuance of additional ordinary fully paid shares under an Employee Awards Plan and requests their quotation on the exchange. The content focuses on the issuance and listing of new securities rather than financial results, management changes, or other report types. This fits the category of announcements related to share issues or capital changes. Therefore, the document is best classified as a Share Issue/Capital Change announcement (SHA). The document length and detail confirm it is not a brief notice or a report publication announcement but a substantive filing about capital changes.
2023-04-18 English
Cleansing Notice 2 pages 155.5KB
Regulatory Filings Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act, which relates to the issuance of securities without disclosure under Part 6D.2 of the Corporations Act. It provides details about the securities issued, compliance statements, and contact information. The document is short (3257 characters) and serves as a regulatory announcement about a share issue rather than a full financial report or detailed capital update. It does not contain financial statements or detailed analysis, nor does it announce a report publication. The content fits best as a Regulatory Filing (RNS) because it is a formal compliance notice related to securities issuance without disclosure, which does not fit other more specific categories like Share Issue/Capital Change (SHA) that typically involve announcements of new share issues with more detail or capital structure changes. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2023-04-18 English
Orthocell commences nerve repair study 3 pages 210.3KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the commencement of a nerve repair study by Orthocell. It discusses the study's purpose, collaborators, market potential, and regulatory context but does not contain any financial statements, detailed financial performance data, or comprehensive report content. It is not an annual or interim report, audit report, earnings release, or any detailed investor presentation. The document is a corporate announcement about a clinical study and strategic development, typical of a regulatory announcement or general company update. It does not fit into categories like M&A, capital updates, or voting results. Given the nature and content, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory or corporate announcements that do not fit other specific categories. The document length and content confirm it is not merely a brief report publication announcement but a substantive announcement. Confidence is high due to clear content and format.
2023-04-17 English
Leading US-based nerve surgeons appointed to advisory board 3 pages 176.1KB
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of two specialist US-based nerve surgeons to the company's Medical Scientific Advisory Board. It focuses on management and advisory board changes, detailing the expertise and roles of the new appointees. There is no financial data, regulatory filing, or report attached or referenced. The content is about changes in the company's advisory board, which falls under Board/Management Information (MANG). The document length is 7588 characters, sufficient for a detailed announcement but not a full report. Therefore, the appropriate classification is MANG with high confidence.
2023-03-28 English
Orthocell Appoints Non-Executive Director Dr Ravi Thadhani 3 pages 238.7KB
Board/Management Information Classification · 95% confidence The document is an announcement regarding the appointment of a new independent Non-Executive Director, Dr. Ravi I. Thadhani, to the board of Orthocell Limited. It details his background, qualifications, and the terms of his appointment, including options granted. There is no financial data, report, or regulatory filing referenced beyond the appointment itself. The content focuses on management changes at the board level, which fits the category of Board/Management Information (MANG). The document length is 8286 characters, which is sufficient for a detailed announcement but does not contain financial statements or report data. Therefore, the appropriate classification is MANG with high confidence.
2023-03-07 English
Notification regarding unquoted securities - OCC 7 pages 31.0KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Notification of Issue, Conversion or Payment up of Unquoted Equity Securities' and details the issuance of unquoted options as part of director appointment terms. It includes specifics about the securities issued, their exercise price, expiry date, and the number of securities issued. The document is an announcement of a securities issuance event, specifically unquoted equity securities (options). It does not contain financial statements, management discussion, or earnings data. It is not a full financial report but rather a regulatory announcement about capital changes related to securities issuance. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length (7789 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2023-03-07 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.